NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has prepared a second supplementary prospectus (the “Supplement Prospectus”) to the prospectus regarding invitation to subscribe for units (the “Rights Issue”) which was approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) on 26 April 2023, and published by the Company on the same day (the “Prospectus”) and the supplement prospectus that was approved by the Swedish Financial Supervisory Authority on 9 May 2023 and published by the Company on the same day (the “Supplement Prospectus 1”).
The Supplement Prospectus has been prepared as Alligator on 11 May 2023 through a press release announced that Orion Corporation, a global pharmaceutical company based in Finland, has selected bispecific lead antibodies and is exercising its option to develop these molecules under the existing research collaboration and license agreement between Alligator and Orion Corporation.
The Supplement Prospectus has been prepared in accordance with Article 23 of the Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”) and was approved by the Swedish Financial Supervisory Authority on 12 May 2023. The Supplement Prospectus is to be considered a part of, and shall be read in connection with, the Prospectus and the Supplement Prospectus 1. The Prospectus, the Supplement Prospectus 1 and the Supplement Prospectus (together the ”Prospectuses”) are available on the Company’s, Aktieinvest FK AB’s and Redeye AB’s respective websites (www.alligatorbioscience.com, www.aktieinvest.se and www.redeye.se), and will also be available on the Swedish Financial Supervisory Authority’s website (www.fi.se).
Investors who, prior to the publication of the Supplement Prospectus, have applied or in any other way consented to subscription of units in the Rights Issue have, according to Article 23 in the Prospectus Regulation, the right to withdraw their application or consent within two business days from the publication of the Supplementary Prospectus, i.e. until and including 16 May 2023. Withdrawal shall be made in writing to Aktieinvest FK AB, Emittentservice, P.O. Box 7415, SE-103 91 Stockholm, Sweden, or via email to firstname.lastname@example.org. Investors who have applied for subscription of units through a nominee shall contact their nominee regarding withdrawal. Application which is not withdrawn within said time will remain binding and investors who wish to keep their application for units do not need to take any actions.
For complete terms and conditions and other information regarding the Rights Issue, please refer to the Prospectus.
DNB Markets, a part of DNB Bank ASA, Sweden Branch and Redeye AB act as Joint Global Coordinators in connection with the Rights Issue. Setterwalls Advokatbyrå AB acts as legal adviser to Alligator in connection with the Rights Issue. Aktieinvest FK AB acts as the issuing agent in connection with the Rights Issue.